Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D

被引：0
|
作者：
Yale, Jean-Francois
Major-Pedersen, Atheline
Catarig, Andrei-Mircea
Jain, Rashmi
Menzen, Markus
Holmes, Patrick
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-797-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
797-P
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety profile of once-weekly subcutaneous semaglutide in a real-world adult population with type 2 diabetes
    Yale, J. -F.
    Major-Pedersen, A.
    Catarig, A. -M.
    Jain, R. G.
    Menzen, M.
    Holmes, P.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S339 - S340
  • [2] Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme
    Yale, Jean-Francois
    Major-Pedersen, Atheline
    Catarig, Andrei-Mircea
    Jain, Rashmi
    Menzen, Markus
    Holmes, Patrick
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4429 - 4440
  • [3] Efficacy and Safety of Once-Weekly Semaglutide in People with Type 1 Diabetes in Real-World Practice
    Bellido, Virginia
    Herguido, Noelia Gros
    Amuedo, Sandra
    Ariza, Luis Baena
    Alfonso, Soto M.
    DIABETES, 2023, 72
  • [4] Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
    Menzen, Markus
    Berentzen, Tina Landsvig
    Catarig, Andrei-Mircea
    Pieperhoff, Sebastian
    Simon, Joerg
    Jacob, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (04) : 205 - 215
  • [5] Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population
    Visaria, Jay
    Uzoigwe, Chioma
    Swift, Caroline
    Dang-Tan, Tam
    Paprocki, Yurek
    Willey, Vincent J.
    CLINICAL THERAPEUTICS, 2021, 43 (05) : 808 - 821
  • [6] Efficacy and safety of once-weekly semaglutide versus sitagliptin as add-on to metformin and/or thiazolidinediones in subjects with T2D (SUSTAIN 2)
    Chow, Francis
    Ahren, Bo
    Comas, Lluis Masmiquel
    Kumar, Harish
    Sargin, Mehmet
    Karsbol, Julie Derving
    Jacobsen, Sanja Hald
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S122 - S122
  • [7] Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
    Garcia de Lucas, Maria Dolores
    Pablo Miramontes-Gonzalez, Jose
    Aviles-Bueno, Beatriz
    Isabel Jimenez-Millan, Ana
    Rivas-Ruiz, Francisco
    Perez-Belmonte, Luis M.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [8] Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)
    Mateos, Irene Caballero
    de Lucas, Maria Dolores Garcia
    Doulatram-Gamgaram, Viyey Kishore
    Moreno-Moreno, Paloma
    Jimenez-Millan, Ana Isabel
    Botana-Lopez, Manuel
    Merino-Torres, Juan Francisco
    Soto-Gonzalez, Alfonso
    Fernandez-Garcia, Jose Carlos
    Morales-Portillo, Cristobal
    NUTRIENTS, 2024, 16 (15)
  • [9] Real-World Effectiveness of Newly Initiated Once-Weekly Semaglutide (sema OW) by Prescriber Specialty
    Shivappa, Nitin
    Noone, Joshua
    Swift, Caroline
    Du, Simo
    Tan, Hiangkiat
    Paprocki, Yurek M.
    Willey, Vincent
    DIABETES, 2021, 70
  • [10] Real-World Effectiveness of Once-Weekly Semaglutide (Sema OW) from a US Commercially Insured and Medicare Advantage Population
    Visaria, Jay
    Uzoigwe, Chioma
    Swift, Caroline
    Paprocki, Yurek M.
    Willey, Vincent
    DIABETES, 2020, 69
12345